Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
12.44B
Market cap12.44B
Price-Earnings ratio
33.19
Price-Earnings ratio33.19
Dividend yield
—
Dividend yield—
Average volume
2.20M
Average volume2.20M
High today
$113.00
High today$113.00
Low today
$108.81
Low today$108.81
Open price
$111.92
Open price$111.92
Volume
1.77M
Volume1.77M
52 Week high
$116.85
52 Week high$116.85
52 Week low
$61.23
52 Week low$61.23

Stock Snapshot

With a market cap of 12.44B, Halozyme Therapeutics(HALO) trades at $109.62. The stock has a price-to-earnings ratio of 33.19.

As of 2026-10-13, Halozyme Therapeutics(HALO) stock has fluctuated between $108.81 and $113.00. The current price stands at $109.62, placing the stock +0.7% above today's low and -3.0% off the high.

The Halozyme Therapeutics(HALO)'s current trading volume is 1.77M, compared to an average daily volume of 2.2M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $116.85 and a 52-week low of $61.23.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $116.85 and a 52-week low of $61.23.

HALO News

Benzinga 10h
Here's How Much $100 Invested In Halozyme Therapeutics 5 Years Ago Would Be Worth Today - Benzinga

...

Here's How Much $100 Invested In Halozyme Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
Simply Wall St 2d
What Investors Are Trying To Figure Out About Halozyme Therapeutics

Halozyme Therapeutics (HALO) just expanded its global collaboration and license deal with argenx, adding two more exclusive ENHANZE targets. The enlarged agreem...

What Investors Are Trying To Figure Out About Halozyme Therapeutics
TipRanks 7d
Halozyme announces Dutch court of the Hague found Merck infringed patents

Halozyme Therapeutics (HALO) announced that the specialized Dutch patent court of the Hague has found Merck (MRK) to be infringing one of its MDASE patents, EP...

Analyst ratings

73%

of 11 ratings
Buy
72.7%
Hold
18.2%
Sell
9.1%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.